Dichotomous miR expression and immune responses following primary blood-stage malaria

Grants

Funding Acknowledgements

Funding for the clinical trials was provided by Medicines for Malaria Venture (MMV) from grants awarded by the Wellcome Trust and Bill and Melinda Gates Foundation. The laboratory work supported by the National Health and Medical Research Council (NHMRC) Australia (Program Grant 1037304). We thank Joerg Moehrle and Tim Wells from MMV, Geneva for facilitating access to study samples from the clinical trials. JG Burel was supported by a UQ International scholarship from the University of Queensland. DLD was supported by an NHMRC Principal Research Fellowship. JSM was supported by an NHMRC Practitioner Fellowship and a Government of Queensland Clinical Research Fellowship. MJB was supported by an NHMRC Early-Career Fellowship. The Burnet Institute is supported by the NHMRC Australia Infrastructure for Research Institutes Support Scheme and the Victorian State Government Operational Infrastructure Support grant. We thank the Q-pharm staff who conducted the human infection studies, in particular Suzanne Elliot, Nannette Douglas and Gem Mackenroth; Paul Griffin; as well as Katharine Trenholme, Fiona Amante, and Silvana Sekuloski for their critical role in the study management. We gratefully acknowledge Thomas Watkins and John Miles for their role in designing the NanoString custom codeset. We also thank the Flow cytometry and Imaging Facility at QIMR Berghofer Medical Research Institute for assistance with flow cytometry. The authors declare no competing financial interests. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.